Find a Pharmacy
Vertice Login
Info banner
A significant part of the Healthesystems vision is to create a more integrated experience for our customers

November 16, 2026

NCCI Reports on GLP-1 Utilization in Workers’ Comp

Back to Regulatory Recap

The National Council on Compensation Insurance (NCCI) recently discussed GLP-1 utilization in their latest Asked & Answered series, which utilizes NCCI data to reply to stakeholder questions.

According to the NCCI, GLP-1 utilization represented about 0.02% of the total medical spend in workers’ comp in 2025 – or $1.9 million out of $9.3 billion in total medical payments. Coincidentally, GLP-1s represented 0.02% of the total claim counts in 2025.

Since the first GLP-1 was approved for weight management in 2021, GLP-1 drugs in workers’ comp have seen an annual growth of nearly 40%. While this may seem significant, the NCCI believes the overall impact on workers’ comp will remain minimal as utilization grows, as GLP-1s represented 0.01% of total medical spend in 2021, increasing to just 0.02% b 2025.

The average payment per GLP-1 has remained relatively stable between $1,200 and $1,300 from 2021-2025.

GLP-1s were most often utilized for injuries associated with lumbar spine, shoulders, and knees. About 40% of GLP-1 claims were reported with a diabetes diagnosis. Among major surgery claims, less than 25% had any GLP-1 prescriptions in the six months prior to surgery.

Subscribe to Regulatory Recap

Get weekly legislation & policy updates straight to your inbox.
lockmap-markermagnifiercrossmenuarrow-leftcross-circle